RONC1 – immunotherapy for pancreatic cancer

RONC1 is Redbiotec’s lead immuno-oncology program, based on the proprietary platform technology of C.O.M.O.S.

RONC1 could be a standalone therapy, or in combination with other immunotherapeutics such as checkpoint inhibitor.

Patent status: pending

Learn more about Redbiotec’s unique technology platform – C.O.M.O.S.